SGLT2 Inhibitor Use May Benefit Patients With HFpEF

SGLT2 inhibitor use may reduce the risk for CV death or hospitalization for heart failure in HF patients with preserved ejection fraction

new heart
Adobe Stock

WEDNESDAY, Dec. 15, 2021 (HealthDay News) -- Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with a decreased risk for cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with heart failure and ejection fraction >40 percent, according to a review and meta-analysis published online Dec. 1 in the European Journal of Preventive Cardiology.

Vasiliki Tsampasian, from University of East Anglia in the United Kingdom, and colleagues conducted a systematic literature review and meta-analysis with a primary end point of CV death and HHF.

Based on five studies (9,726 patients), the researchers found that the use of SGLT2i was associated with a significant reduction in CV death or HHF (hazard ratio [HR], 0.78; 95 percent confidence interval [CI], 0.69 to 0.87) and in HHF (HR, 0.71; 95 percent CI, 0.61 to 0.84) versus placebo. The groups were similar in terms of CV death (HR, 1.01; 95 percent CI, 0.80 to 1.28) and all-cause mortality (HR, 1.01; 95 percent CI, 0.89 to 1.14). When limiting the analysis to data for patients with left ventricular ejection fraction >50 percent (5,928 patients), there was a reduction observed in CV death or HHF (HR, 0.77; 95 percent CI, 0.66 to 0.91) in the SGLT2i group.

"For many years there was not a single medicine that could improve the outcome in patients with the second type of heart failure -- those patients with preserved ejection fraction," a coauthor said in a statement. "This is the first medication that can really improve the outcomes for this patient group, and it will revolutionize the treatment offered to heart failure patients."

Abstract/Full Text

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on December 15, 2021

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ